Loading
A phase 2 trial of Flonoltinib 75mg in myeloproliferative neoplasms, run by Chengdu Zenitar Biomedical Technology Co., Ltd, now recruiting.
Phase IIa Study of Flonoltinib Maleate Tablets in the Treatment of Patients With Polycythemia Vera is a phase 2 interventional study registered as NCT07232290 by Chengdu Zenitar Biomedical Technology Co., Ltd, with 60 participants planned, started 2025-09-23 and due to reach its primary completion in 2027-07-30. Interventions recorded: Flonoltinib 75mg, Flonoltinib 100mg, Flonoltinib 125mg and Extended Phase Dose Group.
Shares Chengdu Zenitar Biomedical Technology and the tag pipeline.
Shares Chengdu Zenitar Biomedical Technology and the tag pipeline.
Shares Chengdu Zenitar Biomedical Technology and the tag pipeline.
Shares Chengdu Zenitar Biomedical Technology and the tag pipeline.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
Shares Chengdu Zenitar Biomedical Technology and the tag pipeline.